465 related articles for article (PubMed ID: 29455554)
1. Synthesis, antitumour and antioxidant activities of novel α,β-unsaturated ketones and related heterocyclic analogues: EGFR inhibition and molecular modelling study.
El-Husseiny WM; El-Sayed MA; Abdel-Aziz NI; El-Azab AS; Ahmed ER; Abdel-Aziz AA
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):507-518. PubMed ID: 29455554
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of 2-styrylquinolines as antitumour agents and EGFR kinase inhibitors: molecular docking study.
El-Sayed MA; El-Husseiny WM; Abdel-Aziz NI; El-Azab AS; Abuelizz HA; Abdel-Aziz AA
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):199-209. PubMed ID: 29251017
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
Bakr RB; Mehany ABM; Abdellatif KRA
Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
[TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
5. Novel series of 6-(2-substitutedacetamido)-4-anilinoquinazolines as EGFR-ERK signal transduction inhibitors in MCF-7 breast cancer cells.
Ismail RSM; Abou-Seri SM; Eldehna WM; Ismail NSM; Elgazwi SM; Ghabbour HA; Ahmed MS; Halaweish FT; Abou El Ella DA
Eur J Med Chem; 2018 Jul; 155():782-796. PubMed ID: 30047410
[TBL] [Abstract][Full Text] [Related]
6. Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
Chang J; Ren H; Zhao M; Chong Y; Zhao W; He Y; Zhao Y; Zhang H; Qi C
Eur J Med Chem; 2017 Sep; 138():669-688. PubMed ID: 28711702
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and anticancer evaluation of novel spirobenzo[h]chromene and spirochromane derivatives with dual EGFR and B-RAF inhibitory activities.
Abdelatef SA; El-Saadi MT; Amin NH; Abdelazeem AH; Omar HA; Abdellatif KRA
Eur J Med Chem; 2018 Apr; 150():567-578. PubMed ID: 29549841
[TBL] [Abstract][Full Text] [Related]
8. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.
Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA
Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and antitumor activity of novel pyrazolo[3,4-d]pyrimidine derivatives as EGFR-TK inhibitors.
Abdelgawad MA; Bakr RB; Alkhoja OA; Mohamed WR
Bioorg Chem; 2016 Jun; 66():88-96. PubMed ID: 27043178
[TBL] [Abstract][Full Text] [Related]
10. Novel quinoline-3-carboxamides (Part 2): Design, optimization and synthesis of quinoline based scaffold as EGFR inhibitors with potent anticancer activity.
Aly RM; Serya RAT; El-Motwally AM; Esmat A; Abbas S; Abou El Ella DA
Bioorg Chem; 2017 Dec; 75():368-392. PubMed ID: 29096097
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and anti-proliferative activity of some new quinoline based 4,5-dihydropyrazoles and their thiazole hybrids as EGFR inhibitors.
George RF; Samir EM; Abdelhamed MN; Abdel-Aziz HA; Abbas SE
Bioorg Chem; 2019 Mar; 83():186-197. PubMed ID: 30380447
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and molecular modeling of biquinoline-pyridine hybrids as a new class of potential EGFR and HER-2 kinase inhibitors.
Sangani CB; Makawana JA; Duan YT; Yin Y; Teraiya SB; Thumar NJ; Zhu HL
Bioorg Med Chem Lett; 2014 Sep; 24(18):4472-4476. PubMed ID: 25172421
[TBL] [Abstract][Full Text] [Related]
13. Novel 4-arylaminoquinazoline derivatives with (E)-propen-1-yl moiety as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells.
Chen L; Zhang Y; Liu J; Wang W; Li X; Zhao L; Wang W; Li B
Eur J Med Chem; 2017 Sep; 138():689-697. PubMed ID: 28711703
[TBL] [Abstract][Full Text] [Related]
14. N-Substituted-4-phenylphthalazin-1-amine-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluation studies.
El-Adl K; Ibrahim MK; Khedr F; Abulkhair HS; Eissa IH
Arch Pharm (Weinheim); 2021 Mar; 354(3):e2000219. PubMed ID: 33197080
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, mechanistic and histopathological studies of small-molecules of novel indole-2-carboxamides and pyrazino[1,2-a]indol-1(2H)-ones as potential anticancer agents effecting the reactive oxygen species production.
Youssif BGM; Abdelrahman MH; Abdelazeem AH; Abdelgawad MA; Ibrahim HM; Salem OIA; Mohamed MFA; Treambleau L; Bukhari SNA
Eur J Med Chem; 2018 Feb; 146():260-273. PubMed ID: 29407956
[TBL] [Abstract][Full Text] [Related]
16. Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors.
Qin X; Lv Y; Liu P; Li Z; Hu L; Zeng C; Yang L
Bioorg Med Chem Lett; 2016 Mar; 26(6):1571-1575. PubMed ID: 26879314
[TBL] [Abstract][Full Text] [Related]
17. Benzo[g]quinazolin-based scaffold derivatives as dual EGFR/HER2 inhibitors.
Ghorab MM; Alsaid MS; Soliman AM; Al-Mishari AA
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):67-73. PubMed ID: 29098904
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and Anti-Proliferative Evaluations of New Heterocyclic Derivatives Using 5,6,8,9-Tetrahydropyrazolo[5,1-b]quinazolin-7(3H)-one Derivatives Derived from Cyclohexa-1,4-dione.
Mahmoud MAA; Alsharif MA; Mohareb RM
Anticancer Agents Med Chem; 2021; 21(4):468-486. PubMed ID: 32445457
[TBL] [Abstract][Full Text] [Related]
19. New Thiazolyl-Pyrazoline Derivatives as Potential Dual EGFR/HER2 Inhibitors: Design, Synthesis, Anticancer Activity Evaluation and In Silico Study.
Fakhry MM; Mattar AA; Alsulaimany M; Al-Olayan EM; Al-Rashood ST; Abdel-Aziz HA
Molecules; 2023 Nov; 28(21):. PubMed ID: 37959874
[No Abstract] [Full Text] [Related]
20. Design, synthesis and biological evaluation of novel benzimidazole-2-substituted phenyl or pyridine propyl ketene derivatives as antitumour agents.
Wu LT; Jiang Z; Shen JJ; Yi H; Zhan YC; Sha MQ; Wang Z; Xue ST; Li ZR
Eur J Med Chem; 2016 May; 114():328-36. PubMed ID: 27017265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
